All News
EULAR 2022 Featured Industry Abstracts
Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
Read Article
RNL 2022: Rheumatoid Arthritis - Best Management
This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:
Read Article
RNL 2022: Spondyloarthritis Spectrum
This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.
- Microbiome in Spondyloathritis - Jose Scher, MD
- Axial Psoriatic Arthritis - Philip Mease, MD
- Juvenile Spondyloathritis - Pamela Weiss, MD
Read Article
Methotrexate Monitoring (5.13.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.
Read Article
New #SLE drug to pay attention to!
iberdomide target Ikaros and Aiolos, reduce B cell, reduce autoAb and reduce IFN sig while enhancing regulatory T cells- Prof T Dorner #EULAR2022 @rheumnow https://t.co/q39pxK3gFJ
TheDaoIndex KDAO2011 ( View Tweet)
Spanish safety registry BIOBADASER 3.0:
*9000+ pts with IMID treated w/ bio or tsDMARDS
*352 pts w/ prior malignancy
*32 incident malignancies
-> 27 events/1000PY
NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups
@RheumNow #EULAR2022
OP0138 https://t.co/8IyC6NdGCF
Aurelie Najm AurelieRheumo ( View Tweet)
#ClinicalPearl #SLE Rx tomorrow? Combine #Ritux+#Belimumab variable response, CART Rx for severe refractory #lupus, antiCD38i, drugs i. RCTs=hope for pts. #EULAR2022 T Dorner @RheumNow @eular_org https://t.co/2BReU5bhG0
Janet Pope Janetbirdope ( View Tweet)
ANCA vasculitis guidelines make sense. Less use of cyclophosphamide was already the case, rituximab can be for induction & maintenance, I am reluctant though in severe disease to stop maintenance Rx at 1 or 2 yrs and go longer as at least 1/3 will relapse beyond 2 yrs. @RheumNow https://t.co/3xRHWya2Uq
Janet Pope Janetbirdope ( View Tweet)
NORD-STAR substudy of coagulation and fibrinolytic parameters:
〽️Impairement in eRA
⚡️Biologic parameters restored by ttmt.
Effect seemed ▶️ with Biologic vs. MTX + GCs
❕No adjustment on disease activity #OP0059 #EULAR2022 @RheumNow https://t.co/CJHldOimBn
Aurelie Najm AurelieRheumo ( View Tweet)
Chen et al. Adalimumab biosimilar (Amgevita) in JIA. Not a switch study, these are initiators. Expected efficacy and safety outcomes of adalimumab seen here. Good to see more of these data to try and break down the last barriers to biosimilars @RheumNow #EULAR2022 POS1294 https://t.co/yoM2dIXLDQ
Richard Conway RichardPAConway ( View Tweet)
Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control.
Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable?
POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU
David Liew drdavidliew ( View Tweet)
Long-term canakinumab data in FMF from RELIANCE registry. 63% in remission at month 24. @RheumNow #EULAR2022 OP0042 https://t.co/mEIoAszmZq https://t.co/IvR1cSG4Aq
Links:
Richard Conway RichardPAConway ( View Tweet)
#POS0263 #EULAR2022 In #rituximab-treated RMD patients with undetectable humoral response to primary #COVID 💉, a study (N=84) found Re-Vaccination with mRNA (2 shots) was better than a Booster (1 shot). Lend support for current approach: 2 + 3rd Primary + Booster @RheumNow https://t.co/AH0wpVKbHc
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k
Links:
Richard Conway RichardPAConway ( View Tweet)
After the #EULAR2022 Recommendations session, it begs the question - Do we follow it?
In Germany, the answer is sometimes
Early bDMARD or JAKi is more frequent in recent years. 1/3 of patients did not receive recommended treatment escalation after 1st csDMARD
POS0234 @Rheumnow https://t.co/0DaP5b7Htc
Eric Dein ericdeinmd ( View Tweet)
To TDM or Not in Rheumatology?
Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation...
https://t.co/u86Vd8bFGr
#MedEdTwitter https://t.co/IpKqPoWM9R
Links:
Dr. John Cush RheumNow ( View Tweet)
🆒 Current indications for #biologics, in inflammatory rheumatic diseases 🔎 such as rheumatoid #arthritis, axSPA, PsA etc... A useful checklist ✅ to keep in the pocket prepared with
@DocFelten #Rheumatology #EULAR2022 https://t.co/cfc4VaF6GZ
Laurent ARNAUD Lupusreference ( View Tweet)
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush RheumNow ( View Tweet)
Biologic Persistence in Psoriatic Arthritis and Psoriasis
Recent studies examined the durability and persistence of biologic agents in patients with PSO and PsA and while some differences were noted overall persistence was low 3 years later.
https://t.co/sqxVaLnXEY https://t.co/yUPWYkRxva
Links:
Dr. John Cush RheumNow ( View Tweet)
From 4 Nordic Registries, 24083 RA patients starting 41K courses of bDMARDs shows RA patients had an 80% higher risk of acute coronary syndromes than in the general population. ACS risk on bDMARDs did not improve at 3yrs or 5 yrs https://t.co/TX3jnIXkrW https://t.co/I34UvWH3qd
Links:
Dr. John Cush RheumNow ( View Tweet)
